These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 8169003)

  • 1. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
    Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
    Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
    Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
    Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
    Thalmann GN; Anezinis PE; Chang SM; Zhau HE; Kim EE; Hopwood VL; Pathak S; von Eschenbach AC; Chung LW
    Cancer Res; 1994 May; 54(10):2577-81. PubMed ID: 8168083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
    Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
    Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
    Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW
    Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.
    Gleave ME; Hsieh JT; von Eschenbach AC; Chung LW
    J Urol; 1992 Apr; 147(4):1151-9. PubMed ID: 1372662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
    Umekita Y; Hiipakka RA; Kokontis JM; Liao S
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel.
    Rhee HW; Zhau HE; Pathak S; Multani AS; Pennanen S; Visakorpi T; Chung LW
    In Vitro Cell Dev Biol Anim; 2001 Mar; 37(3):127-40. PubMed ID: 11370803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant transformation in a nontumorigenic human prostatic epithelial cell line.
    Hayward SW; Wang Y; Cao M; Hom YK; Zhang B; Grossfeld GD; Sudilovsky D; Cunha GR
    Cancer Res; 2001 Nov; 61(22):8135-42. PubMed ID: 11719442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
    Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
    Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
    Thalmann GN; Rhee H; Sikes RA; Pathak S; Multani A; Zhau HE; Marshall FF; Chung LW
    Eur Urol; 2010 Jul; 58(1):162-71. PubMed ID: 19747763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.